GI Windows Corp. scooped up $16.4 million in a series A-1 financing that included investment from Johnson & Johnson Innovation – JJDC Inc., Sonder Capital, GT Healthcare, JC Investco and an unnamed strategic investor. Also participating in the round were new investors Kennedy Trust and Coleman Trust. The funds are earmarked to advance the development and clinical trials of the company’s incisionless anastomosis technology.
Athira Pharma Inc.’s proposed $100 million IPO, along with a filing by Virios Therapeutics LLC to raise $35 million on Aug. 28, helped propel a supercharged amount of investment in 2020 that shows no sign of slowing. The pace is unusually swift this year despite hindrances from COVID-19. The total value of IPOs so far in 2020 is $12.95 billion, with 54 completed, easily outpacing 2019’s $8.64 billion.
Bright days are ahead for China’s biopharmaceutical sector, which is getting a reset from the efforts to tackle COVID-19 through innovation and advancements. “I'm consciously optimistic about the fact that cross-border deals will continue,” Stella Xu, managing director, Quan Capital, from Shanghai, China said during a panel discussion at the Chinabio Partnering Forum.
Triumvira Immunologics Inc., a U.S.-Canadian immuno-oncology startup, has raised $55 million in series A financing to back a pipeline of four new T-cell therapy candidates for the potential treatment of both liquid and solid tumors. Bayer AG's Leaps unit and Northpond Ventures led the round. China-based Oceanpine Capital and Viva Biotech Holdings also provided funds.
DUBLIN – Liquid biopsy developer Freenome Inc. has – literally – capitalized on its recent proof-of-concept AI-Emerge colorectal cancer (CRC) screening study by raising $270 million in a series C round that will enable the South San Francisco firm to complete its ongoing Preempt CRC registration study and to file for pre-market approval from the FDA.
RSS
